SGLT2 inhibitors have been demonstrated to reduce the risk of composite outcomes, including myocardial infarction, stroke, and all-cause mortality, when compared to dipeptidyl peptidase-4 inhibitors [37]. This evidence concerns the gene SLC5A2 and Stroke.